Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies.

1986 ◽  
Vol 4 (3) ◽  
pp. 363-369 ◽  
Author(s):  
N K Cheung ◽  
D D Von Hoff ◽  
S E Strandjord ◽  
P F Coccia
Keyword(s):  
Bone Marrow ◽  
Monoclonal Antibodies ◽  
Neuroblastoma Cells ◽  
Stage Iv ◽  
Soft Agar ◽  
Highly Sensitive ◽  
A Cell ◽  
Tumor Involvement ◽  
Soft Agar Clonogenic Assay ◽  
Murine Monoclonal Antibodies

Three murine monoclonal antibodies (Mab) against a cell surface antigen, the disialoganglioside GD2, were investigated for detecting bone marrow metastasis in patients with neuroblastoma (NB) by indirect immunofluorescence (IF). As few as 0.01% NB cells could be detected. No Mab reactivity was found in 60 non-NB marrows. Thirty-five marrows from patients with stage III and stage IV NB at diagnosis were examined during the course of their disease. Tumor involvement was found in 74% by Mab, 55% by the two-layer soft agar clonogenic assay (CA), and 27% by conventional histochemical stains. All marrows containing NB histologically were positive for tumor by Mab; 71% were also positive by CA. Of histologically negative marrows, 63% were Mab positive, the majority (78%) of which were also positive by CA. All Mab nonreactive samples were negative histologically and by CA. We conclude that these antibodies are highly sensitive and specific in detecting NB metastasis in bone marrow.

Monoclonal Antibodies to a VWF-A2 Decapeptide with the C-Terminal Residue Tyr1605, Generated by ADAMTS13 Cleavage, Develop a Highly Sensitive ELISA for Its Activity and Characterize Upshaw-Schulman Syndrome.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2643-2643 ◽  
Author(s):  
Seiji Kato ◽  
Masanori Matsumoto ◽  
Tomomi Matsuyama ◽  
Hisahide Hiura ◽  
Yoshihiro Fujimura
Keyword(s):  
Monoclonal Antibodies ◽  
Asymptomatic Carrier ◽  
Laboratory Data ◽  
Clinical Manifestations ◽  
Gene Mutations ◽  
Adamts13 Activity ◽  
Severe Deficiency ◽  
Highly Sensitive ◽  
A2 Domain ◽  
Murine Monoclonal Antibodies

Abstract We prepared murine monoclonal antibodies (mAbs) against a decapeptide of the VWF-A2 domain that has a C-terminal Tyr1605, generated by ADAMTS13 cleavage. These mAbs reacted neither with purified VWF nor the pentadecapeptide 1596-DREQAPNLVYMVTGN-1610, unless the Y1605-M1606 bond was cleaved. Using one of these mAbs, we developed a novel and highly sensitive ELISA for ADAMTS13 activity. In this assay, a recombinant VWF polypeptide (D1596–R1668) tagged with GST and His at the ends (GST-VWF73-His), is used as a substrate; upon cleavage by ADAMTS13, two fragments, GST-VWF10 and VWF63-His, are generated. Thus, the amount of GST-VWF10 can be directly measured using our mAb labeled with peroxidase. The specificity of this assay was confirmed by inhibition with EDTA, IgGs purified from thrombotic thrombocytopenic purpura (TTP) patients, and an anti-ADAMTS13 mAb. The detection limit of this assay was 0.5% of the normal. Of 20 patients with congenital TTP (Upshaw-Schulman syndrome, USS) whose ADAMTS13 gene mutations were identified, 14 had a severe deficiency (<0.5%), and 6 had a moderate deficiency (0.55~1.3%) of ADAMTS13 activity. No correlation was found between these two groups in terms of the onset of clinical manifestations. Further, a unique asymptomatic carrier of USS with two mutations (R268P/P475S) in the gene showed 4.2 % of normal plasma ADAMTS13 activity in this novel ELISA, indicating that plasma levels of ADAMTS13 activity between 1.3 and 4.2 % represent a gray zone which may lead to clinical manifestations of TTP. Table 1 shows a clinical and laboratory data of USS patients included in this study. Table 1. Clinical and laboratory data of 20 USS patients

Quantitative Tumor Cell Content of Bone Marrow and Blood as a Predictor of Outcome in Stage IV Neuroblastoma: A Children’s Cancer Group Study

2000 ◽  
Vol 18 (24) ◽  
pp. 4067-4076 ◽  
Author(s):  
Robert C. Seeger ◽  
C. Patrick Reynolds ◽  
Richard Gallego ◽  
Daniel O. Stram ◽  
Robert B. Gerbing ◽  
...  
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Tumor Cell ◽  
Tumor Cells ◽  
Induction Chemotherapy ◽  
Neuroblastoma Cells ◽  
Stage Iv ◽  
Prognostic Impact ◽  
Cancer Group ◽  
Stage Iv Neuroblastoma

PURPOSE: This study investigated the prognostic value of quantifying tumor cells in bone marrow and blood by immunocytology in children with high-risk, metastatic neuroblastoma. PATIENTS AND METHODS: Patients with stage IV neuroblastoma (N = 466) registered on Children’s Cancer Group study 3891 received five cycles of induction chemotherapy and were randomized either to myeloablative chemoradiotherapy with autologous purged bone marrow rescue or to nonmyeloablative chemotherapy. Subsequently, they were randomized to 13-cis-retinoic acid or no further treatment. Immunocytologic analyses of bone marrow and blood were performed at diagnosis, week 4, week 12, bone marrow collection, and end induction and were correlated with tumor biology, clinical variables, treatment regimen, and event-free survival (EFS). RESULTS: Immunocytology identified neuroblastoma cells in bone marrow of 81% at diagnosis, 55% at 4 weeks, 27% at 12 weeks, 19% at bone marrow collection, and 14% at end induction. Tumor cells were detected in blood of 58% at diagnosis and 5% at collection. There was an adverse effect on EFS of increasing tumor cell concentration in bone marrow at diagnosis (P = .04), at 12 weeks (P = .006), at bone marrow collection (P < .001), and at end induction (P = .07). Positive blood immunocytology at diagnosis was associated with decreased EFS (P = .003). The prognostic impact of immunocytology was independent of morphologically detected bone marrow disease, MYCN status, and serum ferritin level in bivariate Cox analyses. CONCLUSION: Immunocytologic quantification of neuroblastoma cells in bone marrow and blood at diagnosis and in bone marrow during induction chemotherapy provides prognostic information that can identify patients with very high-risk disease who should be considered for experimental therapy that might improve outcome.

The use of bone marrow aspirations and lumbar punctures at the time of diagnosis of retinoblastoma.

1989 ◽  
Vol 7 (1) ◽  
pp. 140-143 ◽  
Author(s):  
C B Pratt ◽  
D Meyer ◽  
P Chenaille ◽  
D B Crom
Keyword(s):  
Bone Marrow ◽  
Tumor Cells ◽  
Bone Marrow Involvement ◽  
Stage Iv ◽  
Stage Disease ◽  
Tumor Dissemination ◽  
Systemic Spread ◽  
Response To Chemotherapy ◽  
Tumor Involvement ◽  
Work Up

Lumbar punctures (n = 115) and bone marrow aspirations (n = 114) were performed as part of the routine initial diagnostic evaluation of 115 children with retinoblastoma. Three spinal fluid examinations were positive for tumor cells, and bone marrow smears of three children demonstrated clumps of tumor cells. Five of the six positive studies were in patients with stage IV (extraglobar) disease. These results show that demonstrable CSF or bone marrow involvement is so infrequent an event at diagnosis in patients without symptoms, signs, or histologic evidence of tumor dissemination (stages I-II) as to support a recommendation that these studies need not be performed routinely in such patients. If, after enucleation, there is evidence of extraglobar extension, or if patients have symptoms or signs of CNS or systemic spread (stages III or IV), both procedures should be performed to accurately stage disease and provide baseline measurements of tumor involvement for monitoring of response to chemotherapy and/or irradiation. These results have importance in terms of justification of invasive work-up of most (greater than 85%) affected children, and cost containment.

REMOVAL OF NEUROBLASTOMA CELLS FROM BONE MARROW WITH MONOCLONAL ANTIBODIES CONJUGATED TO MAGNETIC MICROSPHERES

The Lancet ◽  
1984 ◽  
Vol 323 (8368) ◽  
pp. 70-73 ◽  
Author(s):  
J.G Treleaven ◽  
J Ugelstad ◽  
T Philip ◽  
F.M Gibson ◽  
A Rembaum ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Monoclonal Antibodies ◽  
Neuroblastoma Cells ◽  
Magnetic Microspheres

Detection of Neuroblastoma Cells in Human Bone Marrow Using a Combination of Monoclonal Antibodies

Hybridoma ◽  
1982 ◽  
Vol 1 (4) ◽  
pp. 349-368 ◽  
Author(s):  
ZDENKA L. JONAK ◽  
ROGER H. KENNETT ◽  
KATHLEEN B. BECHTOL
Keyword(s):  
Bone Marrow ◽  
Monoclonal Antibodies ◽  
Neuroblastoma Cells ◽  
Human Bone ◽  
Human Bone Marrow

scholarly journals Innovative and Highly Sensitive Detection of Clostridium perfringens Enterotoxin Based on Receptor Interaction and Monoclonal Antibodies

Toxins ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 266
Author(s):  
Thea Neumann ◽  
Maren Krüger ◽  
Jasmin Weisemann ◽  
Stefan Mahrhold ◽  
Daniel Stern ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Clostridium Perfringens ◽  
Food Poisoning ◽  
Receptor Interaction ◽  
Clostridium Perfringens Enterotoxin ◽  
Fast Detection ◽  
Highly Sensitive ◽  
Basic And Applied Research ◽  
Highly Sensitive Detection

Clostridium perfringens enterotoxin (CPE) regularly causes food poisoning and antibiotic-associated diarrhea; therefore, reliable toxin detection is crucial. To this aim, we explored stationary and mobile strategies to detect CPE either exclusively by monoclonal antibodies (mAbs) or, alternatively, by toxin-enrichment via the cellular receptor of CPE, claudin-4, and mAb detection. Among the newly generated mAbs, we identified nine CPE-specific mAbs targeting five distinct epitopes, among them mAbs recognizing CPE bound to claudin-4 or neutralizing CPE activity in vitro. In surface plasmon resonance experiments, all mAbs and claudin-4 revealed excellent affinities towards CPE, ranging from 0.05 to 2.3 nM. Integrated into sandwich enzyme-linked immunosorbent assays (ELISAs), the most sensitive mAb/mAb and claudin-4/mAb combinations achieved similar detection limits of 0.3 pg/mL and 1.0 pg/mL, respectively, specifically detecting recombinant CPE from spiked feces and native CPE from 30 different C. perfringens culture supernatants. The implementation of mAb- and receptor-based ELISAs into a mobile detection platform enabled the fast detection of CPE, which will be helpful in clinical laboratories to diagnose diarrhea of assumed bacterial origin. In conclusion, we successfully employed an endogenous receptor and novel high affinity mAbs for highly sensitive and specific CPE-detection. These tools will be useful for both basic and applied research.

scholarly journals Screening and development of monoclonal antibodies for identification of ferret T follicular helper cells

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Wenbo Jiang ◽  
Julius Wong ◽  
Hyon-Xhi Tan ◽  
Hannah G. Kelly ◽  
Paul G. Whitney ◽  
...  
Keyword(s):  
Animal Model ◽  
Monoclonal Antibodies ◽  
Lymph Node ◽  
Cross Reactivity ◽  
Tfh Cells ◽  
Follicular Helper ◽  
Lymph Node Cells ◽  
Human Viruses ◽  
Humoral Responses ◽  
Murine Monoclonal Antibodies

AbstractThe ferret is a key animal model for investigating the pathogenicity and transmissibility of important human viruses, and for the pre‐clinical assessment of vaccines. However, relatively little is known about the ferret immune system, due in part to a paucity of ferret‐reactive reagents. In particular, T follicular helper (Tfh) cells are critical in the generation of effective humoral responses in humans, mice and other animal models but to date it has not been possible to identify Tfh in ferrets. Here, we describe the screening and development of ferret-reactive BCL6, CXCR5 and PD-1 monoclonal antibodies. We found two commercial anti-BCL6 antibodies (clone K112-91 and clone IG191E/A8) had cross-reactivity with lymph node cells from influenza-infected ferrets. We next developed two murine monoclonal antibodies against ferret CXCR5 (clone feX5-C05) and PD-1 (clone fePD-CL1) using a single B cell PCR-based method. We were able to clearly identify Tfh cells in lymph nodes from influenza infected ferrets using these antibodies. The development of ferret Tfh marker antibodies and the identification of ferret Tfh cells will assist the evaluation of vaccine-induced Tfh responses in the ferret model and the design of novel vaccines against the infection of influenza and other viruses, including SARS-CoV2.

Sign in / Sign up

Export Citation Format

Share Document